Imperative Trial
Study Objective
To assess the safety and efficacy of the Zoom System, including aspiration with 0.088” ID catheters, within 8 hours of symptom onset.
Prospective, consent before groin puncture
26 Thrombectomy-Capable Stroke Centers with Enrolled Patients
0.088” Aspiration Indication as part of the Zoom System
211 Patients with Concomitant Aspiration1
Trial Results
19 min
Median groin puncture to mTICI ≥ 2B2
Fastest time to reperfusion of major prospective MT trials3
4.7%
Rescue device rate
Rescue device rate to achieve 91%
final reperfusion (mTICI2b+)2, 4
Lowest rescue device rate of major prospective MT trials5
26%
Type 3 arches6
Encompassed significantly more type 3 arches than real-world anatomy7
Excellent safety profile
0.5%
Serious vessel injury2
0.9%
sICH2
M2 cohort results8
The Imperative Trial has shown excellent results, including exceptional safety in M2 occlusions.
69
Age, median
55%
mRS 0-1
13
Baseline NIHSS, median
1.5%
sICH
88%
Core-lab final TICI ≥ 2B
Note: individual trials are not directly comparable and data is presented for observational purposes only.
1 Total study population = 260 patients. Results presented include concomitant aspiration cohort only. n=211
2 Zoom System IFU (LBL002069.A), n=211
3 Major MT trials with reperfusion times reported: ARISE II, TIGER, PROST, PENUMBRA 3D, ASTER, COMPASS, DEFUSE 3, DAWN
4 IMPERATIVE Trial data cohort analysis, n=211
5 Major MT trials with rescue rates reported: Compared to: ASTER, COMPASS, ARISE II, TIGER, PROST
6 Mokin et al. INR 2025
7 Mokin et al. Neuroradiology 2021
8 Mascitelli et al. JNIS 2025